PubRank

Pedro Romero

Author PubWeight™ 233.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Pathway Tools software. Bioinformatics 2002 14.89
2 TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007 5.86
3 Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J 2005 5.36
4 Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011 3.97
5 Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004 3.59
6 Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest 2011 3.28
7 Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2007 3.16
8 Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005 3.11
9 Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008 2.94
10 Coupled folding and binding with alpha-helix-forming molecular recognition elements. Biochemistry 2005 2.94
11 "MIATA"-minimal information about T cell assays. Immunity 2009 2.90
12 The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics 2008 2.72
13 Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008 2.15
14 Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry 2007 1.93
15 EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannose trimming. J Biol Chem 2006 1.91
16 Harmonization of immune biomarker assays for clinical studies. Sci Transl Med 2011 1.84
17 Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol 2009 1.81
18 Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005 1.81
19 Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 2003 1.78
20 D²P²: database of disordered protein predictions. Nucleic Acids Res 2012 1.75
21 New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006 1.74
22 BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2009 1.71
23 Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol 2002 1.68
24 In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A 2007 1.65
25 Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 2009 1.63
26 Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A 2009 1.61
27 Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 2008 1.59
28 Rational drug design via intrinsically disordered protein. Trends Biotechnol 2006 1.57
29 Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007 1.55
30 MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 2013 1.51
31 Improving protein order-disorder classification using charge-hydropathy plots. BMC Bioinformatics 2014 1.50
32 Transcriptional profiling of Caulobacter crescentus during growth on complex and minimal media. J Bacteriol 2004 1.46
33 Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 2002 1.44
34 Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 2002 1.42
35 Conservation of intrinsic disorder in protein domains and families: I. A database of conserved predicted disordered regions. J Proteome Res 2006 1.42
36 Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med 2003 1.41
37 Heat shock cognate protein 70 is involved in rotavirus cell entry. J Virol 2002 1.37
38 Rotavirus gene silencing by small interfering RNAs. EMBO Rep 2002 1.36
39 Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 2010 1.33
40 Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods 2005 1.33
41 The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol 2009 1.32
42 Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol 2007 1.32
43 Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res 2012 1.30
44 Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun 2004 1.29
45 Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J Immunol 2006 1.28
46 Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum Gene Ther 2002 1.27
47 Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother 2004 1.27
48 Conservation of intrinsic disorder in protein domains and families: II. functions of conserved disorder. J Proteome Res 2006 1.27
49 Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res 2011 1.25
50 Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol 2009 1.25
51 Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J Exp Med 2002 1.25
52 Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 2007 1.25
53 Exploring the binding diversity of intrinsically disordered proteins involved in one-to-many binding. Protein Sci 2013 1.23
54 Regulation of monocyte functional heterogeneity by miR-146a and Relb. Cell Rep 2012 1.19
55 Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 2003 1.17
56 Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J Immunol 2002 1.17
57 Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest 2014 1.16
58 Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 2012 1.16
59 NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells. J Immunol 2012 1.14
60 TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res 2011 1.14
61 Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells. J Immunol Methods 2006 1.13
62 Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets. J Transl Med 2011 1.13
63 A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 2006 1.13
64 Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 2011 1.13
65 Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol 2008 1.12
66 Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res 2006 1.11
67 Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 2002 1.11
68 In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 2002 1.10
69 Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol 2009 1.09
70 CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 2002 1.09
71 Interaction of rotaviruses with Hsc70 during cell entry is mediated by VP5. J Virol 2003 1.08
72 gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res 2004 1.08
73 Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J Immunol 2003 1.07
74 Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol 2003 1.07
75 Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res 2004 1.07
76 Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res 2014 1.06
77 Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 2010 1.04
78 Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies. J Immunol 2009 1.04
79 Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 2002 1.03
80 Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time. J Immunol 2009 1.01
81 Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer 2010 1.01
82 The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 2011 1.00
83 Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res 2013 1.00
84 Distinct mechanisms control human naive and antigen-experienced CD8+ T lymphocyte proliferation. J Immunol 2006 1.00
85 Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun 2003 1.00
86 Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res 2003 1.00
87 SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest 2013 1.00
88 Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol 2005 0.99
89 Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin Cancer Biol 2003 0.99
90 Molecular biology of rotavirus cell entry. Arch Med Res 2002 0.98
91 Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase. J Immunol 2009 0.98
92 LiveCount Assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8(+) T-cells by flow cytometry. J Immunol Methods 2006 0.98
93 High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. Eur J Immunol 2005 0.98
94 Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. Immunol Res 2006 0.97
95 Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res 2003 0.97
96 Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol 2002 0.97
97 In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. J Immunol 2007 0.97
98 Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther 2008 0.96
99 Use of phycoerythrin and allophycocyanin for fluorescence resonance energy transfer analyzed by flow cytometry: advantages and limitations. Cytometry 2002 0.96
100 Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol 2010 0.96
101 Disease-driven T cell activation predicts immune responses to vaccination against melanoma. Cancer Immun 2003 0.96
102 Analysis of the kinetics of transcription and replication of the rotavirus genome by RNA interference. J Virol 2009 0.96
103 Intrinsic disorder in Viral Proteins Genome-Linked: experimental and predictive analyses. Virol J 2009 0.96
104 Recent advances and hurdles in melanoma immunotherapy. Pigment Cell Melanoma Res 2009 0.95
105 Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. Int J Cancer 2011 0.95
106 Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci U S A 2008 0.94
107 Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. Int J Cancer 2010 0.94
108 Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol 2006 0.94
109 Intrinsic protein disorder and protein-protein interactions. Pac Symp Biocomput 2012 0.94
110 MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function. J Biol Chem 2012 0.93
111 Toward improved immunocompetence of adoptively transferred CD8+ T cells. J Clin Invest 2005 0.93
112 Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res 2009 0.93
113 Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology 2012 0.92
114 A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. J Immunol 2007 0.92
115 Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages. J Immunol 2007 0.92
116 The peptide-binding and ATPase domains of recombinant hsc70 are required to interact with rotavirus and reduce its infectivity. J Virol 2006 0.92
117 Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide. J Immunother 2007 0.91
118 High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res 2004 0.91
119 The spike protein VP4 defines the endocytic pathway used by rotavirus to enter MA104 cells. J Virol 2012 0.91
120 Announcing the tumor immunology and biological cancer therapy section (edited by iSBTc) of the Journal of Translational Medicine. J Transl Med 2009 0.91
121 IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. J Immunol 2007 0.90
122 A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. J Transl Med 2011 0.90
123 Rotavirus RRV associates with lipid membrane microdomains during cell entry. Virology 2004 0.90
124 The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol 2014 0.89
125 Rotavirus prevents the expression of host responses by blocking the nucleocytoplasmic transport of polyadenylated mRNAs. J Virol 2013 0.89
126 Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol Immunother 2006 0.89
127 Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother 2008 0.89
128 Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int J Cancer 2012 0.88
129 Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity. Eur J Immunol 2002 0.88
130 Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity. MBio 2010 0.88
131 Subclassifying disordered proteins by the CH-CDF plot method. Pac Symp Biocomput 2012 0.88
132 Melanoma immunotherapy: past, present, and future. Curr Pharm Des 2005 0.88
133 Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Int J Cancer 2009 0.88
134 Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother 2007 0.88
135 Valproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4-positive cells through inhibition of histone deacetylase. J Biol Chem 2010 0.87
136 Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes. Eur J Immunol 2002 0.86
137 Characterization of an influenza A virus in Mexican swine that is related to the A/H1N1/2009 pandemic clade. Virology 2012 0.86
138 Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL. J Immunol 2002 0.85
139 Virus-like particles induce robust human T-helper cell responses. Eur J Immunol 2011 0.85
140 Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles. Immunol Cell Biol 2006 0.85
141 Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. Cancer Immunol Immunother 2007 0.85
142 Vaccination route matters for mucosal tumors. Sci Transl Med 2013 0.85
143 Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunol Immunother 2014 0.85
144 VP7 mediates the interaction of rotaviruses with integrin alphavbeta3 through a novel integrin-binding site. J Virol 2004 0.84
145 Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells? Cancer Immun 2002 0.84
146 Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. J Immunother 2010 0.84
147 Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunol Immunother 2007 0.83
148 Toward synthetic combinatorial peptide libraries in positional scanning format (PS-SCL)-based identification of CD8+ Tumor-reactive T-Cell Ligands: a comparative analysis of PS-SCL recognition by a single tumor-reactive CD8+ cytolytic T-lymphocyte clone. Cancer Res 2002 0.83
149 Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition. Cancer Immun 2002 0.83
150 Adverse effects of pharmacological therapy for nicotine addiction in smokers following a smoking cessation program. Nicotine Tob Res 2005 0.83
151 Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells. Blood 2010 0.82
152 Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells. Blood 2003 0.82
153 Human thymus exports naive CD8 T cells that can home to nonlymphoid tissues. J Immunol 2004 0.82
154 Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. J Immunol 2006 0.82
155 Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor. Int Immunol 2008 0.81
156 Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. Proc Natl Acad Sci U S A 2011 0.80
157 MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med 2014 0.80
158 Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens. Regul Toxicol Pharmacol 2010 0.80
159 Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines. Vaccine 2011 0.79
160 Chronic inflammation is regarded as a strong promoter of tumorigenesis. Int J Cancer 2010 0.79
161 Premenstrual asthma and atopy markers. Ann Allergy Asthma Immunol 2010 0.79
162 Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. Eur J Immunol 2006 0.79
163 CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Cancer Immunol Immunother 2012 0.78
164 Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships. PLoS One 2013 0.78
165 Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses. Methods Mol Biol 2010 0.78
166 Premenstrual asthma and symptoms related to premenstrual syndrome. J Asthma 2010 0.78
167 Metabolic effects of regular physical exercise in healthy population. Endocrinol Nutr 2013 0.78
168 Toll-like receptor 3 is necessary for dsRNA adjuvant effects. Vaccine 2009 0.78
169 Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. Cell Immunol 2004 0.78
170 Structured reporting of T cell assay results. Cancer Immun 2013 0.77
171 Classical cardiovascular risk factors according to fasting plasma glucose levels. Eur J Intern Med 2007 0.77
172 An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain. Cancer Immun 2008 0.77
173 MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cancer Immunol Immunother 2010 0.77
174 Lack of functionally active Melan-A(26-35)-specific T cells in the blood of HLA-A2+ vitiligo patients. J Invest Dermatol 2008 0.77
175 Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations. Int J Cancer 2002 0.77
176 Methods for the ex vivo characterization of human CD8+ T subsets based on gene expression and replicative history analysis. Methods Mol Med 2005 0.77
177 Secondary structure, a missing component of sequence-based minimotif definitions. PLoS One 2012 0.77
178 Tinkering with nature: the tale of optimizing peptide based cancer vaccines. Cancer Treat Res 2005 0.77
179 Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients. PLoS One 2013 0.76
180 Tumor cell recognition efficiency by T cells. PLoS Med 2005 0.75
181 Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant. J Immunother 2009 0.75
182 Recent advances in tumour antigen-specific therapy: in vivo veritas. Int J Cancer 2005 0.75
183 What is the influence of vaccination's routes on the regression of tumors located at mucosal sites? Oncoimmunology 2012 0.75
184 JTM's Tumor immunology goes broad: announcing the Immunobiology and Immunotherapy section. J Transl Med 2013 0.75
185 Lipid A in cancer therapy. Foreword. Adv Exp Med Biol 2009 0.75
186 [Immunotherapy for head and neck squamous cell carcinoma]. Rev Med Suisse 2006 0.75
187 Corrigendum: the antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 2015 0.75
188 Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells. J Immunol 2004 0.75
189 [Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma]. Bull Cancer 2007 0.75
190 Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen. Int J Cancer 2002 0.75
191 SITC 26th annual meeting--summary. J Transl Med 2012 0.75
192 [Role of atherogenic dyslipidemia in the development of metabolic syndrome]. Med Clin (Barc) 2006 0.75
193 Correction: Valproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4-positive cells through inhibition of histone deacetylase. J Biol Chem 2011 0.75